Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Assessment of the Antitumour Effect of Zoledronic Acid in Patients With Multiple Myeloma and Asymptomatic Biochemical Relapse: Prospective Clinical Trial of the GEM/PETHEMA Group

NCT01087008 is registered in ClinicalTrials.gov with PETHEMA Foundation as lead sponsor.

NCT NCT01087008
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01087008 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Assessment of the Antitumour Effect of Zoledronic Acid in Patients With Multiple Myeloma and Asymptomatic Biochemical Relapse: Prospective Clinical Trial of the GEM/PETHEMA Group
Lead sponsor
PETHEMA Foundation
Phase
Phase 4
Overall status
Completed
Start date
April 30, 2010
Completion date
June 5, 2013
Enrollment
103 (estimated)
Sites
16

Conditions

As the registry lists them; a condition with its own page is linked.

multiple myeloma